Synthesis and preclinical pharmacological evaluation of a novel 99mTc–shikonin as a potential tumor imaging agent

M. Motaleb; N. Al-Musayeib; W. Zaghary; H. Shweeta

doi:10.1007/s10967-012-1701-6

Jump to Content

Journal of Radioanalytical and Nuclear Chemistry

Volume/Issue:: Volume 293: Issue 1

Synthesis and preclinical pharmacological evaluation of a novel ^99mTc–shikonin as a potential tumor imaging agent

Authors:

M. Motaleb

M. Motaleb Labeled Compounds Department, Hot Labs Center, Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt

Search for other papers by M. Motaleb in
Current site
Google Scholar
PubMed

N. Al-Musayeib

N. Al-Musayeib Pharmacognosy Department, Faculty of Pharmacy, King Saud University, Riyadh, 11451 Saudi Arabia

Search for other papers by N. Al-Musayeib in
Current site
Google Scholar
PubMed

W. Zaghary

W. Zaghary Pharmaceutical Chemistry Department, Faculty of Pharmacy, King Saud University, Riyadh, 11451 Saudi Arabia

Search for other papers by W. Zaghary in
Current site
Google Scholar
PubMed

, and

H. Shweeta

H. Shweeta Organic Chemistry Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudia Arabia

Search for other papers by H. Shweeta in
Current site
Google Scholar
PubMed

View More View Less

Pages:: 391–396

Online Publication Date:: 07 Mar 2012

Publication Date:: 01 Jul 2012

Article Category:: Research Article

DOI:: https://doi.org/10.1007/s10967-012-1701-6

Keywords:: Shikonin; Extraction; Ratanjot pigment; 99mTc; Tumor

Restricted access

Abstract

Shikonin was isolated from Ratanjot pigment then the obtained shikonin was well characterized. This study is aimed to optimize radiolabeling yield of shikonin with ^99mTc with respect to factors that affect the reaction conditions such as shikonin amount, SnCl₂·2H₂O amount, reaction time and pH of the reaction mixture. In vitro stability of the radiolabeled complex was checked and it was found to be stable for up to 6 h. Biodistribution studies showed that, ^99mTc–shikonin accumulate in tumor sites with higher T/NT than other currently available ^99mTc(CO)₃-VIP, ^99mTc–nitroimidazole analogues and ^99mTc–polyamine analogues indicating that shikonin deliver ^99mTc to the tumor sites with a percentage sufficient for imaging and can overcome many drawbacks of other radiopharmaceuticals used for tumor imaging.

Save
Cite
Email this content

Share Link

Copy this link, or click below to email it to a friend
Email this content
or copy the link directly:

https://akjournals.com/abstract/journals/10967/293/1/article-p391.xml
The link was not copied. Your current browser may not support copying via this button.

Link copied successfully

Collapse
Expand

Journal of Radioanalytical and Nuclear Chemistry

Print ISSN:: 0236-5731

Online ISSN:: 1588-2780

To see the editorial board, please visit the website of Springer Nature.

Manuscript Submission: HERE

For subscription options, please visit the website of Springer Nature.

Journal of Radionalytical and Nuclear Chemistry
Language	English
Size	A4
Year of Foundation	1968
Volumes per Year	1
Issues per Year	12
Founder	Akadémiai Kiadó
Founder's Address	H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher	Akadémiai Kiadó Springer Nature Switzerland AG
Publisher's Address	H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. CH-6330 Cham, Switzerland Gewerbestrasse 11.
Responsible Publisher	Chief Executive Officer, Akadémiai Kiadó
ISSN	0236-5731 (Print)
ISSN	1588-2780 (Online)